How Do Antibody-drug conjugates (ADCs) Impact Cancer-Associated Cellular Senescence?
Cellular senescence in cancer is characterized by irreversible growth arrest and the secretion of pro-inflammatory factors collectively known as the senescence-associated secretory phenotype (SASP). Traditional chemotherapeutics may inadvertently induce senescence in normal tissues, promoting chronic inflammation and possibly tumor recurrence. In contrast, ADCs offer the advantage of localized drug delivery, thereby reducing the risk of systemic senescence induction.
Moreover, Antibody-drug conjugates (ADCs) are being investigated not only for their cytotoxic potential but also for their capacity to induce "therapeutic senescence" in cancer cells. This strategy could lead to tumor suppression by halting cell proliferation and activating immune-mediated clearance of senescent cells. Certain payloads, such as microtubule inhibitors, are preferred over DNA-damaging agents to limit off-target senescence and avoid long-term tissue damage.
Created: 01 Aug 2025 04:08:46 AM
All Replies (0)
There are no replies to this discussion.